HOBOKEN, N.J., June 28, 2011 /PRNewswire/ -- Octapharma USA recently hosted an International Physician Advisory Board in New York City, bringing together medical experts from around the world who have extensive experience internationally with taking care of patients with von Willebrand's Disease (VWD). As the most common inherited bleeding disorder in humans, VWD affects one to two percent of the general population or approximately 3 million people in the United States.
Octapharma manufactures wilate®, a therapy introduced to the U.S. market for VWD over the last year that has been available in many other countries for a decade. The U.S. Food and Drug Administration (FDA) has granted Octapharma orphan drug exclusivity for wilate® (von Willebrand Factor/Factor VIII Concentrate, Human), the first replacement therapy developed specifically for VWD.
"Our goal was to promote a scientific dialogue among the medical community in the U.S. and abroad," said Octapharma USA President Flemming Nielsen. "Overall the advisory meeting's clinical platform encouraged significant discussion and debate around the treatment and management of VWD patients and evaluated data and experiences in Europe. There was general agreement among the attendees that improving the care for VWD patients is possible and that more data either from clinical trials or scientific experience would be beneficial."
The meeting was jointly chaired by Jerry S. Powell, M.D., Professor at the University at California-Davis and Director of the UC-Davis Hemophilia and Thrombosis Center; and John Pasi, M.D., Professor of Haemostasis and Thrombos